

## Metabolic Dysfunction-Associated Steatotic Liver Disease Committee meeting 01

**Date:** 16/07/2025

**Location:** Virtual (Zoom)

**Minutes:** Final

<b>Committee members present:</b>	
Marie Burnham	Present for items 1 – 13
Phil Newsome	Present for items 1 – 7
Michael Paul Gregg	Present for items 1 – 13
Stephen James Hanna	Present for items 1 – 13
Benjamin Rea	Present for items 1 – 7
Pinelopi Manousou	Present for items 1 – 13
Mathis Heydtmann	Present for items 1 – 13
Emma Ashley	Present for items 1 – 13
Christopher D Byrne	Present for items 1 – 13
Rohit Sinha	Present for items 1 – 13
Helen Gwenllian Jarvis	Present for items 1 – 13
Emmanouil Tsochatzis	Present for items 1 – 13
Jake Mann	Present for items 1 – 13

<b>In attendance:</b>		
Bethan Dorsett	Senior Guidance Content Designer	Present for items 1 – 13
Caroline Mulvihill	Topic Lead	Present for items 1 – 13
Emily Terrazas-Cruz	Senior Technical Analyst	Present for items 1 – 7
Maria Smyth	Technical Analyst	Present for items 1 – 13
Patrick Langford	Technical Analyst	Present for items 1 – 13
Paul Levay	Senior Information Specialist	Present for items 1 – 13
Steph Armstrong Manby	Senior Health Economist	Present for items 1 – 13
Syed Mohiuddin	Health Economics Adviser	Present for items 1 – 13
Tamara Diaz	Project Manager	Present for items 1 – 13
Toby Mercer	Technical Analyst	Present for items 1 – 13
Jessica Bailey	Public Involvement Adviser	Present for items 1 – 13
Tara Chernick	Implementation support	Present for items 1 – 13

Laurie Tomlinson	London School of Hygiene and Tropical Medicine (LSHTM)	Present for items 1 – 13
Giulia Seghezze	LSHTM	Present for items 1 – 13
Fred Martineau	LSHTM	Present for items 1 – 13

<b>Apologies:</b>	
Chioma Nmereobasi Izzie-Engbeaya	Consultant Endocrinologist and Obesity physician
Carole Pitkeathley	Lay member
Martin Allaby	Consultant Clinical Adviser, NICE

<b>1. Welcome and apologies</b>
<p>The Chair welcomed the Committee members and attendees to the 1<sup>st</sup> MASLD guideline committee meeting.</p> <p>The Chair informed the Committee that apologies had been received. These are noted above.</p>
<b>2. Participant Introductions</b>
<p>The Chair led introductions by all participants and teams, including: the NICE guideline development team, INTEGRATE project team from the LSHTM, NICE Public and Community Involvement and Content Design teams.</p>
<b>3. Overview of the NICE Guideline Development Team</b>
<p>The meeting was updated by CM on the composition and functions of the NICE team supporting the guideline. An overview was provided on each phase leading through to publication. Committee member vacancies were also flagged for the information of attendees.</p>
<b>4. Introduction to the INTEGRATE project team</b>
<p>LT, NIHR Research Professor at the London School of Hygiene and Tropical Medicine (LSHTM), delivered a detailed presentation to the committee, introducing the INTEGRATE team's role in the MASLD guideline.</p>
<b>5. Scope of the Guideline</b>
<p>The meeting was updated by CM on the scope of the guideline, which includes diagnosis, monitoring, and questions around dietary supplements and alcohol. Pharmacological treatments will be addressed via NICE Technology Appraisals.</p>

<b>6. Review questions</b>
TM and MS delivered a presentation outlining the review questions, and the methodology and proposed approach for reviewing clinical evidence on diagnostics.
<b>7. Protocols: Diagnostic questions</b>
TM, MS and ETC, led an overview of the draft protocol for this topic. The proposed protocols focused diagnostic accuracy and diagnostic effectiveness when identifying people with MASLD.
<b>8. Public involvement in NICE guidelines</b>
JB delivered a presentation on how the committee will involve and engage with patients, carers, and the public throughout the guideline development process, in line with NICE’s commitment to inclusive and transparent working.
<b>9. Introduction to Health Economics</b>
SA-M provided an introduction to health economics and introduced SM as the HE Lead supporting the guideline.
<b>10. Declaration of interests</b>
A brief presentation on NICE’s conflicts of interest policy was delivered by CM.
<b>11. Equality and health inequalities impact assessment</b>
The meeting was reminded of NICE’s duty to consider health inequalities.
<b>12. Next steps and any other business</b>
The Chair thanked members for their participation. There being no further business the meeting ended at 3:30 p.m.

<b>Date of next meeting:</b>	GC 02: 19 September 2025
<b>Location of next meeting: (Hybrid meeting)</b>	<b>Remote participants:</b> Joining by Zoom available <b>In person participants:</b> Meeting will be held at the NICE London offices, 2nd Floor   2 Redman Place   London   E20 1JQ